What is Ablexis?
Ablexis operates a cutting-edge transgenic mouse platform engineered for the accelerated discovery and development of therapeutic antibodies. Their proprietary AlivaMab-X Mouse technology is recognized for generating enhanced immune responses, positioning Ablexis as a leader in the biopharmaceutical sector. The company also offers flexible licensing agreements, catering to the specific requirements of its clientele, which primarily includes pharmaceutical and biotechnology firms concentrating on antibody-based drug candidates.
How much funding has Ablexis raised?
Ablexis has raised a total of $12M across 1 funding round:
Series A
$12M
Series A (2010): $12M with participation from Third Rock Ventures
Key Investors in Ablexis
Third Rock Ventures
Third Rock Ventures is a prominent healthcare venture capital firm established in 2007, dedicated to identifying and nurturing disruptive scientific and medical innovations. They focus on building companies that aim to significantly improve patient outcomes through a combination of scientific insight, strategic leadership, and operational expertise.
What's next for Ablexis?
With a substantial enterprise-level funding context, Ablexis is poised for significant scaling and further innovation in its antibody discovery services. The strategic investment likely signals a phase of accelerated research and development, potentially expanding its platform capabilities and market reach. Future endeavors may involve forging new partnerships and advancing its pipeline of therapeutic antibody solutions, solidifying its role in the competitive landscape of drug development.
See full Ablexis company page
